

BELEAVE ANNOUNCES PRE-LICENSE INSPECTION DATE

Toronto, ON – March 10th, 2017 - Beleave Inc. ("**Beleave**" or the "**Company**") (CSE: BE) is pleased to announce that Health Canada has scheduled a pre-license inspection of Beleave's facility on March 15, 2017.

About Beleave

Beleave Inc. is a biotech company committed to becoming a licensed producer under the *Access to Cannabis for Medical Purposes Regulations* (the "**ACMPR**"). Beleave's wholly-owned subsidiary First Access Medical Inc. ("**FAM**") has applied for a license to cultivate and sell medical cannabis pursuant to the ACMPR. As of the date hereof, FAM has successfully advanced past the review stage, and scheduled its pre-licensing inspection. Beleave's purpose-built facility is located near Hamilton, Ontario.



Forward-Looking Statements

This news release contains forward-looking statements. The use of any of the words "anticipate", "continue", "estimate", "expect", "may", "will", "project", "should", "believe" and similar expressions are intended to identify forward-looking statements. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. This news release includes forward-looking statements with respect to the completion of the ACMPR licensing process, meeting the requirements of the ACMPR, obtaining a license to cultivate pursuant to the ACMPR, and the start of production. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this news release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in the Company's disclosure documents, which can be found under the Company's profile on www.sedar.com.

For more information contact:

Sebastian de Kloet
Phone: 1 (905) 979 - 5173
Email: Sebastian@beleave.com